advertisement
Abstract #74244 Published in IGR 19-1
Prostaglandin-associated periorbitopathy
Zhang F; Liao S; Liu K; Duan XCChinese Journal of Ophthalmology 2017; 53: 637-640
Glaucoma is one of the leading causes of blindness in the world, second to cataract. The treatment of glaucoma mainly includes drugs, laser and operation, which can slow down the progress of the disease. Prostaglandin is the first-line medication at present. With the constant promotion of clinical application, the local side effects have been found, such as conjunctival congestion, lash lengthening, periorbital and iris pigment deepening, blepharitis and macular edema. As people pay more attention to appearance, periorbitopathy caused by prostaglandin has been reported in recent years, including upper eyelid ptosis and dermatochalasis, deepening of the upper eyelid sulcus, periorbital fat loss, enophthalmos and inferior scleral exposure. The mechanism, performance and treatment methods of these prostaglandin-associated periorbitopathies are reviewed. (Chin J Ophthalmol, 2017, 53: 637-640).
Department of Ophthalmology, Second Xiangya Hospital, Central South University, Changsha 410011, China.
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)
